Menu
← Oncology Approval Tracker
FDA DECISION ·
Darzalex + Kyprolis + dexamethasone
daratumumab + carfilzomib + dexamethasone · Janssen Biotech and Onyx Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after one to three previous lines of therapy.
LAMPGEN ANALYSIS
Why it matters
Added a proteasome inhibitor and anti-CD38 combination for relapsed or refractory myeloma.
What research teams should watch
Align carfilzomib and daratumumab schedules and review baseline cardiac function and transfusion needs.
PRIMARY RECORDS